106%+ returns, 97% win rate: A fresh list of AI-picked stock is out NOW
NEW YORK - SIGA Technologies , Inc. (NASDAQ:SIGA) reported fourth quarter revenue of $81.4 million and earnings per share of $0.63, as the commercial-stage pharmaceutical company continued to see strong product sales. The stock edged up 1.25% following the earnings release.
For the full year 2024, SIGA generated product sales of $133.3 million, up 2% from $130.7 million in 2023. This marks the second consecutive year of product revenue growth for the company. Total (EPA:TTEF) revenue for 2024 came in at $138.7 million, compared to $139.9 million the previous year.
The company reported pre-tax operating income of $70 million and net income of $59.2 million for 2024. Diluted earnings per share for the year were $0.82, down from $0.95 in 2023.
"2024 was a year of strong financial performance and operational execution for SIGA in which we delivered $133 million in product sales and $70 million of pre-tax operating income," said Diem Nguyen, Chief Executive Officer of SIGA Technologies.
SIGA’s fourth quarter product sales included approximately $60 million to the U.S. Strategic National Stockpile, $9 million to the U.S. Department of Defense, and $11 million in international sales. The company has received procurement orders for oral TPOXX from 30 countries over the past three years.
Looking ahead, Nguyen added, "As we enter 2025, we remain focused on durable growth and impact, supported by approximately $70 million of outstanding procurement orders."
In January 2025, SIGA announced that its TPOXX treatment received regulatory approval in Japan for smallpox, mpox, cowpox, and complications following smallpox vaccination in adults and pediatric patients weighing at least 13 kg.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.